FHTX Valuation

Foghorn Therapeutics Inc

Add to Watchlist

Advanced Chart

5.100

+0.12(2.410%)1D

Overview
Forecast
Valuation
Earnings

FHTX Relative Valuation

FHTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, FHTX is overvalued; if below, it's undervalued.

Historical Valuation

Foghorn Therapeutics Inc (FHTX) is now in the Fair zone, suggesting that its current forward PS ratio of 9.48 is considered Fairly compared with the five-year average of -4.63. The fair price of Foghorn Therapeutics Inc (FHTX) is between 4.66 to 7.29 according to relative valuation methord.

Relative Value

Fair Zone

4.66-7.29

Current Price：5.10

Fair

-3.40

Trailing

Forward

-1.09

EV/EBITDA

Foghorn Therapeutics Inc. (FHTX) has a current EV/EBITDA of -1.09. The 5-year average EV/EBITDA is -2.27. The thresholds are as follows: Strongly Undervalued below -8.50, Undervalued between -8.50 and -5.39, Fairly Valued between 0.84 and -5.39, Overvalued between 0.84 and 3.96, and Strongly Overvalued above 3.96. The current Forward EV/EBITDA of -1.09 falls within the Historic Trend Line -Fairly Valued range.

-1.06

EV/EBIT

Foghorn Therapeutics Inc. (FHTX) has a current EV/EBIT of -1.06. The 5-year average EV/EBIT is -2.06. The thresholds are as follows: Strongly Undervalued below -7.32, Undervalued between -7.32 and -4.69, Fairly Valued between 0.57 and -4.69, Overvalued between 0.57 and 3.20, and Strongly Overvalued above 3.20. The current Forward EV/EBIT of -1.06 falls within the Historic Trend Line -Fairly Valued range.

9.48

Foghorn Therapeutics Inc. (FHTX) has a current PS of 9.48. The 5-year average PS is 83.83. The thresholds are as follows: Strongly Undervalued below -274.68, Undervalued between -274.68 and -95.43, Fairly Valued between 263.08 and -95.43, Overvalued between 263.08 and 442.33, and Strongly Overvalued above 442.33. The current Forward PS of 9.48 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Foghorn Therapeutics Inc. (FHTX) has a current P/OCF of 0.00. The 5-year average P/OCF is -3.09. The thresholds are as follows: Strongly Undervalued below -9.67, Undervalued between -9.67 and -6.38, Fairly Valued between 0.20 and -6.38, Overvalued between 0.20 and 3.49, and Strongly Overvalued above 3.49. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-3.71

P/FCF

Foghorn Therapeutics Inc. (FHTX) has a current P/FCF of -3.71. The 5-year average P/FCF is -3.18. The thresholds are as follows: Strongly Undervalued below -7.08, Undervalued between -7.08 and -5.13, Fairly Valued between -1.22 and -5.13, Overvalued between -1.22 and 0.73, and Strongly Overvalued above 0.73. The current Forward P/FCF of -3.71 falls within the Historic Trend Line -Fairly Valued range.

Foghorn Therapeutics Inc (FHTX) has a current Price-to-Book (P/B) ratio of -3.63. Compared to its 3-year average P/B ratio of 194.77 , the current P/B ratio is approximately -101.86% higher. Relative to its 5-year average P/B ratio of 122.48, the current P/B ratio is about -102.96% higher. Foghorn Therapeutics Inc (FHTX) has a Forward Free Cash Flow (FCF) yield of approximately -32.44%. Compared to its 3-year average FCF yield of -18.21%, the current FCF yield is approximately 78.17% lower. Relative to its 5-year average FCF yield of -11.58% , the current FCF yield is about 180.24% lower.

-3.63

P/B

Median3y

194.77

Median5y

122.48

-32.44

FCF Yield

Median3y

-18.21

Median5y

-11.58

Competitors Valuation Multiple

The average P/S ratio for FHTX's competitors is 9.02, providing a benchmark for relative valuation. Foghorn Therapeutics Inc Corp (FHTX) exhibits a P/S ratio of 9.48, which is 5.10% above the industry average. Given its robust revenue growth of 9.71%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

FHTX.O

Foghorn Therapeutics Inc

Monte Rosa Therapeutics Inc

Mereo BioPharma Group PLC

8.90

267.28M

LCTX.A

Lineage Cell Therapeutics Inc

Performance Decomposition

Market capitalization of FHTX decreased by 38.41% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 6.89M to 7.56M.

The secondary factor is the P/E Change, contributed -19.26%to the performance.

Overall, the performance of FHTX in the past 1 year is driven by Revenue Growth. Which is more sustainable.

9.71%

6.89M → 7.56M

Revenue Growth

-28.86%

-333.61 → -237.34

Margin Expansion

-19.26%

-5.14 → -4.15

P/E Change

-38.41%